molecule inhibitor ac2 26  (TargetMol)

Journal: Synthetic and Systems Biotechnology

Article Title: Leveraging ANXA1 to enhance recombinant protein yields in CHO cells: A UPR-Mediated bioprocessing approach

doi: 10.1016/j.synbio.2025.12.001

Figure Lengend Snippet: Schematic overview of the experimental workflow for generating ANXA1-knockdown CHO cell lines and AC2-26 inhibitor treatment. (A) Generation and validation of ANXA1-knockdown cell lines for rADM antibody production. (B) AC2-26 inhibitor treatment in low-producer CHO cells (ADM-14) and subsequent rADM expression analysis.

Article Snippet: On day 3 of suspension culture, the small molecule inhibitor AC2-26 (Topscience Co., Ltd., China) was added [ ], using DMSO (Solarbio Life Sciences, China) as the solvent control.

Techniques: Knockdown, Biomarker Discovery, Expressing

Journal: Synthetic and Systems Biotechnology

Article Title: Leveraging ANXA1 to enhance recombinant protein yields in CHO cells: A UPR-Mediated bioprocessing approach

doi: 10.1016/j.synbio.2025.12.001

Figure Lengend Snippet: AC2-26 effect on ADM-14 CHO cells. (A) Cell density/viability under AC2-26 treatment (n = 3). (B) rADM expression by Western blot with quantification (n = 3). (C) ANXA1 mRNA/protein comparison (n = 3). Quantification was performed using ImageJ (for Western blot densitometry) and GraphPad Prism 10 (for statistical analysis). (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001). n: represents independent biological replicates.

Article Snippet: On day 3 of suspension culture, the small molecule inhibitor AC2-26 (Topscience Co., Ltd., China) was added [ ], using DMSO (Solarbio Life Sciences, China) as the solvent control.

Techniques: Expressing, Western Blot, Comparison

Journal: Current Oncology

Article Title: Prostate Cancer Biomarkers with a Focus on Galectin-3: Emerging Clinical and Therapeutic Implications

doi: 10.3390/curroncol33050280

Figure Lengend Snippet: Compartment-specific functions of Galectin-3 and therapeutic targeting strategies in prostate cancer.

Article Snippet: Melanoma & HNSCC , Immune Escape: Gal-3 acts as a negative immune checkpoint, blocking anti-PD-1 antibody binding to T-cells. , Belapectin + Pembrolizumab , Small molecule Galectin-3 inhibitor , Phase I study showed objective response rates of 50% (melanoma) and 33% (HNSCC). Demonstrates that Gal-3 inhibitors may enhance immunotherapy by reversing immune suppression [ , ]. .

Techniques:

Journal: Current Oncology

Article Title: Prostate Cancer Biomarkers with a Focus on Galectin-3: Emerging Clinical and Therapeutic Implications

doi: 10.3390/curroncol33050280

Figure Lengend Snippet: Compartment-specific functions of Galectin-3 and therapeutic targeting strategies in prostate cancer.

Article Snippet: Lung & Pancreatic Cancer , KRAS Addiction: Gal-3 supports pro-survival pathways in KRAS-driven tumors. , GB1107 , Novel small molecule Galectin-3 inhibitor , Identified as a druggable vulnerability in hard-to-treat tumors, showing Gal-3 as a key mediator of oncogenic signaling beyond the AR pathway [ ]. .

Techniques: